Professor, Neurology, Wayne State University School of Medicine
Neurology
Dr. Peter A. LeWitt, MD
|
|
Give Review
Doctor Peter A. LeWitt, MD is an expert in the field of Neurology. He went to medical school at Warren Alpert Medical School of Brown University. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Peter LeWitt is a published physician. He has 99 publications published. The most current publication "Influence of repeated levodopa administration on rabbit striatal serotonin metabolism, and comparison between striatal and CSF alterations." He accepts Medicare payments and is registered with Medicare.gov.
Publications
- CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.
- Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
- 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis.
- Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.
- Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.
- Norepinephrine: the next therapeutics frontier for Parkinson's disease.
- Comparison of dysphagia before and after deep brain stimulation in Parkinson's disease.
- Is levodopa toxic?: Insights from a brain bank.
- Localizing imbalance in progressive supranuclear palsy: is the thalamus the "fall guy"?
- "Sensory trick" in hemichorea-hemiballism and in Parkinson's disease tremor.
- Relief of parkinsonism and dyskinesia: one and the same dopaminergic mechanism?
- Mao-B inhibitor know-how: back to the pharm.
- Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.
- Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease.
- Levodopa for the treatment of Parkinson's disease.
- Protection against Parkinson's disease progression: clinical experience.
- Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
- A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.
- Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
- Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.
- Clinical trials of neuroprotection for Parkinson's disease.
- Early complement activation increases in the brain in some aged normal subjects.
- Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
- Subcutaneously administered apomorphine: pharmacokinetics and metabolism.
- New developments in levodopa therapy.
- In situ hybridization for detection of nocardial 16S rRNA: reactivity within intracellular inclusions in experimentally infected cynomolgus monkeys--and in Lewy body-c...
- Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program.
- Nocardia asteroides culture filtrates cause dopamine depletion and cytotoxicity in PC12 cells.
- Altered guanosine and guanine concentrations in rabbit striatum following increased dopamine turnover.
- Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.
- The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
- Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group.
- "Paradoxical clonus": rhythmic contractions evoked in passively shortened muscle.
- Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, r...
- A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains.
- Electrophoresis and immunoblot of cerebrospinal fluid proteins in spasmodic torticollis.
- Ineffective treatment of essential tremor with an alcohol, methylpentynol.
- Comparison of methods for analysis of CSF proteins in patients with Alzheimer's disease.
- Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.
- PNU intoxication.
- Severity of Parkinson's disease and the dosage of bromocriptine.
- Hyperhidrosis and hypothermia responsive to oxybutynin.
- A randomized, controlled trial of remacemide for motor fluctuations in Parkinson''s disease.
- Levodopa in the treatment of Parkinson's disease: a consensus meeting.
- Genetic analysis of three patients with an 18p- syndrome and dystonia.
- Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson''s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidat...
- Suppression of neuroleptic-induced persistent abnormal movements in Cebus apella monkeys by enantiomers of 3-PPP.
- Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
- Recent advances in the treatment of Parkinson''s disease: the role of bromocriptine.
- The class of 1975: a differential diagnosis.
- Levodopa in the treatment of Parkinson's disease: current controversies.
- Identification of motor and nonmotor wearing-off in Parkinson''s disease: comparison of a patient questionnaire versus a clinician assessment.
- Rotigotine: a viewpoint by Peter LeWitt.
- CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson''s disease.
- Recent advances in CSF biomarkers for Parkinson''s disease.
- TCH346 as a neuroprotective drug in Parkinson''s disease: a double-blind, randomised, controlled trial.
- Reduction of dyskinesias and psychiatric disability with clozapine over different time courses.
- Levodopa therapeutics for Parkinson''s disease: new developments.
- AAV2-GAD gene therapy for advanced Parkinson''s disease: a double-blind, sham-surgery controlled, randomised trial.
- Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson''s disease.
- Urate as a predictor of the rate of clinical decline in Parkinson disease.
- Movement Disorder Society-sponsored revision of the Unified Parkinson''s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
- Apomorphine therapy in Parkinson''s disease: a review.
- Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson''s disease: a double-blind, randomized, multicenter clinical trial (6002-US-...
- Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study.
- Neuroprotection for Parkinson''s disease.
- Lack of evidence for Nocardia asteroides in brain specimens from Lewy body-containing disorders.
- Influence of age and gender on the levels of histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid.
- Comparison of PCR and culture for detection of Nocardia asteroides in brain specimens from experimentally infected BALB/c mice.
- Characterization of dopamine-depleting activity of Nocardia asteroides strain GUH-2 culture filtrate on PC12 cells.
- Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases.
- The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
- Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.
- A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.
- Ceruloplasmin immunoreactivity in neurodegenerative disorders.
- Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience.
- Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
- Influence of repeated levodopa administration on rabbit striatal serotonin metabolism, and comparison between striatal and CSF alterations.
- Time-dependent effects of levodopa on regional brain dopamine metabolism and lipid peroxidation.
- Micrographia after thalamo-mesencephalic infarction.
- New delivery systems for antiparkinsonian drugs.
- Penicillamine as a controversial treatment for Wilson's disease.
- Measurement of acute phase proteins in the rat brain: contribution of vascular contents.
- The challenge of managing mild Parkinson's disease.
- New drugs for the treatment of Parkinson's disease.
- L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion.
- Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism.
- Monoamine changes in the brain of BALB/c mice following sub-lethal infection with Nocardia asteroides (GUH-2).
- Purine-induced alterations of dopamine metabolism in rat pheochromocytoma PC12 cells.
- Evaluation of a measurement strategy for Parkinson''s disease: assessing patient health-related quality of life.
- Effect of aging on tyrosine hydroxylase protein content and the relative number of dopamine nerve terminals in human caudate.
- Glutamate and other CSF amino acids in Alzheimer's disease.
- Deprenyl''s effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group.
- Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study.
- Effects of (+)-4-propyl-9-hydroxynaphthoxazine on midbrain dopamine neurons: an electrophysiological study.
- Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/levodopa (Sinemet CR4) in Parkinson's disease.
- Orthostatic tremor: the phenomenon of 'paradoxical clonus'.
- Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine.
Schools
The Warren Alpert Medical School Of Brown University
Philadelphia Genl Hospital University Pe
Stanford University Med Center
National Institute Health
Procedures Preformed
- EEG (Electroencephalogram)
- EMG (Electromyography)
- Nerve Block, Somatic
- Non-Cosmetic Chemodenervation
Doctors Specialties
- Neurological Movement Disorders
- Neurology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Stanford University -
Warren Alpert Medical School of Brown University
Hospital
-
Henry Ford Hospital
Drug Facts
| NPI NUMBER | 1750434114 | |
| NPPES Provider LastName | LEWITT | |
| NPPES Provider FirstName | PETER | |
| NPPES Provider ZIPCode | 483223013 | |
| NPPES Provider State | MI | |
| Specialty Description | Neurology | |
| Total Claim Count | 3421.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 28.0 | |
| Percent Opioid Claims | 0.82 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1750434114 |
| Last Name Of The Provider | LEWITT |
| First Name Of The Provider | PETER |
| View All |
Similar Doctors
|
Dr. Steven H. Schechter, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth C. Smith, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Bashiruddin K. Ahmad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Danette C. Taylor, DO |
|
Dr. Amy L. Pappas, DO |